Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2001

View Archived Issues

Licensing opportunity from NIH: analogues of thalidomide as potential angiogenesis inhibitors

NIH licensing opportunity: methods and compositions for inhibiting HIV-coreceptor interactions

Antiinfluenza activity of BioCryst's cyclopentane neuraminidase inhibitor studied

Introgen's INGN-241 demonstrates potent antitumor properties in preclinical studies

Avant initiates second phase IIb trial of TP-10 in infants

Xenova reports Q1 highlights; merger with Cantab completed

Postprandial TG-lowering effects of NK-104 investigated in animal model

FM-VP4 highlighted at recent AHA conference as novel therapy for cardiovascular disease

Active metabolite of leflunomide proven to suppress eotaxin production

Therapeutic pipeline update provided by BioChem Pharma

Cannabinoid receptor agonist reduces IOP in monkeys with and without glaucoma

GSK designs and characterizes a new, high-affinity, selective PPARdelta agonist

Baxter seeks FDA approval to evaluate Neuprex for Crohn's disease

FDA clears phase II trials of novel immunosuppressive drug

Independent DSMB recommends continuation of phase III Theratope trial

Polypeptide with potential in gene therapy for immunodeficiency discovered at Hayashibara

Safety of mitoxantrone in MS patients highlighted at AAN meeting

Durect completes clinical portion of DUROS sufentanil phase II trial

MCH antagonists and use in obesity disclosed by Takeda

Potent and selective alpha1-adrenoceptor ligands reported by Lundbeck

Bivalent FVIIa/TF/FXa complex inhibitors

Shionogi prepares and tests new CB2 receptor ligands

Prostaglandin derivatives claimed by Taisho for inducing sleep, Rx of renal and cardiac disorders

Inhibitors of protein prenyltransferases identified by Dutch researchers

Company Profile: Conforma Therapeutics

NicOx nitric oxide-releasing steroid shows no blanching effect in phase I

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....